Ecology & Environment, Inc. Message Board

Analysts at JP Morgan Cazenove raised their price target on shares of Sprint Nextel from $6.00 to $8.00 in a research note to investors on Tuesday. They now have an "overweight" rating on the stock

Schwab just ugraded to C to B

Analysts at Zacks reiterated a "neutral" rating on shares of Zalicus in a research note to investors on Wednesday. They now have a $1.00 price target on the stock. Zacks' analyst wrote, " Zalicus Stock is starting to look very interesting at this level. The stock has been basing nicely between $0.60 and $0.80 as traders no doubt are waiting for the big phase 2 data on potential blockbuster drug Z160 coming in the fourth quarter 2013. But now might be the time value biotech investors take a look at the stock. The currently market capitalization is only $82 million. That's less than 5X our projected 2013 revenues of $17.0 million, and 45% of the market capitalization is supported by the cash balance. With Z160 a potential blockbuster and the top-line supporting the stock at today's price, Zalicus could be poised for a big second half of the year. Our rating is Neutral', but currently under-review."

Analysts at Oppenheimer reiterated an "outperform" rating on shares of Zalicus in a research note to investors on Wednesday. They now have a $2.00 price target on the stock. The analysts wrote, "Investors remain focused on the two ongoing Z160 Phase IIa proof-of-concept studies in chronic neuropathic pain. Zalicus now expects to report top-line data from these studies by late-2H13. As a reminder, the two Phase IIa studies include Lumbosacral Radiculopathy (LSR) and Postherpetic Neuralgia (PHN). Zalicus stated that it will continue the clinical development of Z944 in 2013. A key US patent was issued in February 2013 that provides coverage through April 2029. We believe that, with total cash of $36.4M at YE12, Zalicus is capitalized past data readout of its two Z160 Phase IIa studies and into 2014."